ROCKVILLE, Md. and SUZHOU, China, April 23, 2025 (GLOBE NEWSWIRE) — Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to address global unmet medical needs primarily for hematological malignancies, today announced that results from two clinical studies of the Bcl-2 selective inhibitor lisaftoclax (APG-2575) and the Read More ›

ROCKVILLE, Md. and SUZHOU, China, April 21, 2025 (GLOBE NEWSWIRE) — Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to address global unmet medical needs primarily for hematological malignancies, today announced that two of its proprietary novel drugs have been included in the 2025 Chinese Society Read More ›

Revenue in 2024 increased 342% year-over-year to US$134.3 million (RMB980.7 million), attributable in part to Takeda’s option payment and strong sales growth of olverembatinib Sales of olverembatinib in China in 2024 increased 52% year-over-year to US$33.0 million Completion of U.S. initial public offering on Nasdaq in January 2025, resulting in US$132.5 million in net proceeds Lisaftoclax Read More ›

ROCKVILLE, Md. and SUZHOU, China, March 25, 2025 (GLOBE NEWSWIRE) — Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to address global unmet medical needs primarily for hematological malignancies, today announced that five abstracts highlighting the latest preclinical results from its pipeline programs have been selected for Read More ›

ROCKVILLE, Md. and SUZHOU, China, March 12, 2025 — Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to address global unmet medical needs primarily for hematological malignancies, today announced that it will release full year 2024 financial results, and provide an update on recent developments on Read More ›

ROCKVILLE, MD, the United States, and SUZHOU, China, March 5, 2025—Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to address global unmet medical needs primarily for hematological malignancies, today announced that its drug, olverembatinib, has been granted a Breakthrough Therapy Designation (BTD) by the Center for Read More ›

ROCKVILLE, Md. and SUZHOU, China, Feb. 07, 2025 — Ascentage Pharma (Nasdaq: AAPG, HKEX: 6855) announced today that the underwriters of its underwritten U.S. initial public offering (the “Offering”) have partially exercised their over-allotment option to purchase an additional 935,144 American depositary shares (“ADSs”) at the initial public offering price of $17.25 per ADS less Read More ›

ROCKVILLE, Md. and SUZHOU, China, Jan. 28, 2025 — Ascentage Pharma (Nasdaq: AAPG) (HKEX: 6855) announced today the closing of its U.S. initial public offering of 7,325,000 American depositary shares (“ADSs”), at a public offering price of $17.25 per ADS, before underwriting discounts and commissions. Each ADS represents four ordinary shares of Ascentage Pharma. The Read More ›

January 26, 2025 (U.S. Eastern Time) – Ascentage Pharma Group International (Nasdaq: AAPG, HKEX: 6855) (the “Company” or “Ascentage Pharma”) announced its official listing on the Nasdaq Global Market today, becoming the first 18A company to achieve a dual listing on the U.S. stock market. This milestone marks the beginning of a new global chapter Read More ›

ROCKVILLE, Md. and SUZHOU, China, Jan. 23, 2025 — Ascentage Pharma (Nasdaq: AAPG) (HKEX: 6855) announced today the pricing of its U.S. initial public offering of 7,325,000 American depositary shares (“ADSs”), at a public offering price of $17.25 per ADS, before underwriting discounts and commissions. Each ADS represents four ordinary shares of Ascentage Pharma. The Read More ›